Software solution with SEND compatible outputs

SEND (Standard for Exchange of Nonclinical Data) describes a structured way to submit nonclinical data in a consistent format to U.S. Food and Drug Administration (FDA). SEND aims to improve the efficiency and quality of the Investigative New Drug (IND) and New Drug Application (NDA) processes.

SEND submission is now mandatory for single dose toxicity, repeat-dose toxicity, carcinogenicity, cardiovascular and respiratory studies.  However, the flexible interpretation of these guidelines and resulting variability in the output datasets1 can cause delays and inefficiencies in the review process.

As an industry partner with deep expertise in IND-enabling studies, emka TECHNOLOGIES helps nonclinical scientists comply with SEND requirements by generating SEND 3.1 compatible tables directly from emka TECHNOLOGIES software.

The data can easily be exported to .xls, .csv and integrated into third-party solutions by Instem and Xybion to increase productivity in preclinical studies.

Main features

  • Selection of SEND variables for each domain
  • Semi-automatic population of the domains wherever possible.
  • Choice lists available with the full CDISC terminology
  • Management of the format codes from the implementation guide
  • Preview SEND-formatted data ready to be exported as .xls or .csv files
  • No need to re-validate your acquisition system. SEND export module works with any
    IOX version.

Download the brochure 

References and additional reading

Other posts you may like

Happy Holidays from all of us at emka TECHNOLOGIES

Please take note that our offices will be closed during holidays. Consult the dates here.

Pharmacology 2019

December 15-17, 201 Edinburgh, UK Booth #14

Molecular Biology Society of Japan

December 03-06, 2019 Fukuoka, Japan

American Epilepsy Society

December 06-10, 2019 Baltimore, USA Booth #120